Study identifies biomarker that could predict whether colon cancer patients benefit from chemotherapy

Study identifies biomarker that could predict whether colon cancer patients benefit from chemotherapy

Many people with stage II or III colon cancer receive additional, or adjuvant, chemotherapy following surgery. However, clinical trials have shown that this treatment doesn’t improve the chances of survival for every patient. A study published July 25 in Cell Reports Medicine identifies and validates a 10-gene biomarker that potentially predicts whether a stage II or III colon cancer patient will benefit from adjuvant chemotherapy.

​Medical Xpress – latest medical and health news stories

Read More

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *